PDCD1 and cancer: Subsequently, the anti-PD-1 mAbs, nivolumab (Opdivo®, Bristol-Myers Squibb) and pembrolizumab (Keytruda®, Merck & Co.)have gained regulatory approvals for the treatment of different cancers.